Alpha Tau Medical Ltd. (DRTS)

Market Cap	216.76M
Revenue (ttm)	n/a
Net Income (ttm)	-29.64M
Shares Out	69.92M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,094
Open	3.150
Previous Close	3.120
Day's Range	3.060 - 3.150
52-Week Range	1.750 - 3.400
Beta	0.86
Analysts	Strong Buy
Price Target	8.00 (+158.07%)
Earnings Date	Nov 19, 2024

About DRTS

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multifor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: DRTS
• Website: https://www.alphatau.com

Analyst Forecast

According to 2 analysts, the average rating for DRTS stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 158.07% from the latest price.

Price Target

$8.0

(158.07% upside)

Analyst Consensus: Strong Buy